Cryoport Croissance future
Future contrôle des critères 0/6
Cryoport devrait augmenter ses bénéfices et ses revenus de 9.7% et de 9.2% par an respectivement, tandis que le BPA devrait croître de croître de 12.6% par an.
Informations clés
9.7%
Taux de croissance des bénéfices
12.63%
Taux de croissance du BPA
| Life Sciences croissance des bénéfices | 17.6% |
| Taux de croissance des recettes | 9.2% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 06 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour de l'analyse • May 03
CYRX: Bullish Coverage And New Cryogenic Platform Will Support Future Upside
Narrative Update on Cryoport Analysts have nudged their price target on Cryoport higher to about $13.61 from roughly $13.22, citing fresh bullish coverage and updated assumptions for revenue growth, discount rate, profit margin, and future P/E as key drivers of the revised view. Analyst Commentary Recent bullish coverage reflects a more constructive stance on Cryoport, with analysts formalizing their view through fresh research initiations and updated valuation work.
Mise à jour de l'analyse • Apr 19
CYRX: Bullish Coverage And New Freezer Launch Will Test Execution Outlook
Analysts have modestly lifted their price target on Cryoport to $9.51, supported by updated assumptions around discount rates, revenue growth, profit margin, and future P/E that align with recently bullish research coverage on the stock. Analyst Commentary Recent research commentary around Cryoport reflects a mix of optimism and caution.Mise à jour de l'analyse • Apr 03
CYRX: Bullish Freezer Launch And Execution Risks Will Shape Future Returns
Narrative Update The analyst price target for Cryoport has edged higher to $9.51 from $9.50, as analysts highlight supportive assumptions around fair value, revenue growth, discount rate, profit margin and future P/E, supported by recent bullish initiation commentary. Analyst Commentary Even with a slightly higher average price target of $9.51, bearish analysts highlight several areas of concern that could limit upside if company execution falls short of expectations.Mise à jour de l'analyse • Mar 20
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have modestly adjusted their price targets on Cryoport, reflecting updated views on revenue growth expectations, slightly lower discount rates, and a small change in projected profit margins and future P/E. Together, these factors fine tune, rather than overhaul, their $ based valuation case.Mise à jour de l'analyse • Mar 04
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have trimmed their price target on Cryoport to $9.50 from $9.50, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and forward P/E, while keeping their view of fair value unchanged. What's in the News Cryoport issued full-year 2026 revenue guidance in a range of $190.0 million to $194.0 million, outlining expectations based on its current business and various external factors, including macroeconomic conditions, supply chains, inflation, government policy, trade restrictions, currency movements and SEC reported risk factors (company guidance).Mise à jour de l'analyse • Feb 18
CYRX: New Cryogenic Freezer Platform Will Support Long Term Margin Prospects
Analysts have made a small trim to their $9.50 price target on Cryoport, reflecting slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping their fair value view broadly intact. What's in the News Cryoport launched the MVE Fusion 800 Series, a self sustaining cryogenic freezer that removes the need for a continuous liquid nitrogen supply, aiming to provide reliability, safety, and energy efficiency in a compact format suitable for space constrained labs and facilities (Key Developments).Mise à jour de l'analyse • Feb 04
CYRX: Modest Buybacks And Margin Outlook Will Support Measured Long Term Prospects
Analysts have adjusted their Cryoport price target slightly to reflect marginally higher perceived risk and a slightly lower forward P/E assumption, while still anticipating modest improvements in profit margin. What's in the News The company reported no share repurchases from July 1, 2025 to September 30, 2025 under the buyback announced on August 6, 2024, leaving that authorization unused in the period (Key Developments).Mise à jour de l'analyse • Jan 21
CYRX: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have nudged their price target on Cryoport slightly lower to US$13.22. This reflects modest tweaks to discount rate assumptions, slightly softer revenue growth expectations, a small uplift in forecast profit margins and a minor adjustment to the future P/E multiple.Mise à jour de l'analyse • Jan 06
CYRX: Higher 2025 Guidance And Buybacks Will Support Measured Long Term Prospects
Analysts have trimmed their price targets on Cryoport to reflect a slightly lower assumed future P/E multiple, while keeping fair value estimates steady. Updated views on discount rates and future revenue contraction narrow but do not materially change the long term margin outlook.Mise à jour de l'analyse • Dec 20
CYRX: Higher Guidance And New Facilities Will Support Measured Long Term Prospects
Analysts have nudged their price target on Cryoport higher by approximately 19 percent, now implying a fair value closer to 9.50 dollars per share. They cite slightly improved long term revenue expectations and modestly better profit margin forecasts, despite a marginally higher discount rate.Mise à jour de l'analyse • Dec 06
CYRX: Improving Gross Margins And $400 Million Cash Will Drive Upside
Analysts have lifted their price target on Cryoport to $15.00 from $10.00, citing improving gross margins, accelerating product revenue growth, and a solid cash position that helps offset prior policy related concerns. Analyst Commentary Bullish analysts view the recent price target increase as evidence that the market is beginning to look past prior policy related uncertainties and refocus on Cryoport's improving fundamentals.Mise à jour de l'analyse • Nov 22
CYRX: Rising Gross Margins and $400 Million Cash Will Support Recovery
The analyst consensus price target for Cryoport has increased by $5. This reflects improving gross margins, stronger product revenue growth, and a more favorable market outlook according to analysts.Mise à jour de l'analyse • Nov 06
CYRX: Improved Gross Margin And Cash Strength Will Drive Rebound
Analysts have raised their price target for Cryoport by $1.11 to $13.22. They cite improved gross margin, stronger product revenue growth, and increased confidence as market conditions stabilize.Mise à jour de l'analyse • Aug 07
Cold Chain Expansion Will Support Cell And Gene Therapies
Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.Article d'analyse • Jul 22
Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 1.4x Cryoport, Inc. ( NASDAQ:CYRX ) may be sending very bullish signals at...Article d'analyse • May 30
Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable
Key Insights Cryoport will host its Annual General Meeting on 6th of June Salary of US$921.2k is part of CEO Jerry...Article d'analyse • Apr 09
Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Nouvelle analyse • Mar 30
New IntegriCell And CXHV3 Systems Will Improve Cell Therapy Supply
Rapid expansion in Life Sciences Services and support for cell and gene therapies are key drivers of Cryoport's revenue growth.Article d'analyse • Mar 06
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price
Shareholders of Cryoport, Inc. ( NASDAQ:CYRX ) will be pleased this week, given that the stock price is up 17% to...Article d'analyse • Feb 22
Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower
Cryoport, Inc. ( NASDAQ:CYRX ) shareholders won't be pleased to see that the share price has had a very rough month...Article d'analyse • Dec 03
Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Cryoport, Inc. ( NASDAQ:CYRX ) is a stock worth...Article d'analyse • Nov 06
Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d'analyse • Aug 09
The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More
Those holding Cryoport, Inc. ( NASDAQ:CYRX ) shares would be relieved that the share price has rebounded 36% in the...Article d'analyse • Jul 22
Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Article d'analyse • Jun 25
Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch
Unfortunately for some shareholders, the Cryoport, Inc. ( NASDAQ:CYRX ) share price has dived 28% in the last thirty...Article d'analyse • Apr 15
Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk
It's not a stretch to say that Cryoport, Inc.'s ( NASDAQ:CYRX ) price-to-sales (or "P/S") ratio of 3.7x right now seems...Article d'analyse • Mar 15
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
It's been a mediocre week for Cryoport, Inc. ( NASDAQ:CYRX ) shareholders, with the stock dropping 15% to US$14.73 in...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 231 | -40 | 12 | N/A | 3 |
| 12/31/2027 | 213 | -34 | -13 | 5 | 9 |
| 12/31/2026 | 194 | -39 | -24 | -7 | 9 |
| 3/31/2026 | 183 | -45 | -26 | -1 | N/A |
| 12/31/2025 | 176 | -42 | -28 | -9 | N/A |
| 9/30/2025 | 172 | -48 | -35 | -15 | N/A |
| 6/30/2025 | 166 | -38 | -38 | -17 | N/A |
| 3/31/2025 | 161 | -104 | -38 | -17 | N/A |
| 12/31/2024 | 157 | -113 | -38 | -16 | N/A |
| 9/30/2024 | 173 | -158 | -36 | -8 | N/A |
| 6/30/2024 | 190 | -175 | -45 | -11 | N/A |
| 3/31/2024 | 208 | -117 | -46 | -7 | N/A |
| 12/31/2023 | 169 | -93 | -46 | -1 | N/A |
| 9/30/2023 | 236 | -55 | -41 | 0 | N/A |
| 6/30/2023 | 241 | -47 | -32 | 3 | N/A |
| 3/31/2023 | 248 | -38 | -29 | 0 | N/A |
| 12/31/2022 | 237 | -45 | -26 | -2 | N/A |
| 9/30/2022 | 233 | -296 | -27 | -3 | N/A |
| 6/30/2022 | 230 | -297 | -23 | 5 | N/A |
| 3/31/2022 | 222 | -293 | -12 | 15 | N/A |
| 12/31/2021 | 223 | -284 | -17 | 8 | N/A |
| 9/30/2021 | 215 | -76 | -25 | -4 | N/A |
| 6/30/2021 | 169 | -78 | -32 | -18 | N/A |
| 3/31/2021 | 122 | -77 | -34 | -22 | N/A |
| 12/31/2020 | 79 | -75 | -25 | -15 | N/A |
| 9/30/2020 | 40 | -22 | -11 | -4 | N/A |
| 6/30/2020 | 38 | -23 | -6 | 0 | N/A |
| 3/31/2020 | 37 | -20 | -5 | 0 | N/A |
| 12/31/2019 | 34 | -18 | N/A | -1 | N/A |
| 9/30/2019 | 30 | -20 | N/A | -2 | N/A |
| 6/30/2019 | 26 | -9 | N/A | -2 | N/A |
| 3/31/2019 | 22 | -9 | N/A | -2 | N/A |
| 12/31/2018 | 20 | -10 | N/A | -3 | N/A |
| 9/30/2018 | 17 | -10 | N/A | -4 | N/A |
| 6/30/2018 | 15 | -9 | N/A | -5 | N/A |
| 3/31/2018 | 13 | -9 | N/A | -4 | N/A |
| 12/31/2017 | 12 | -8 | N/A | -4 | N/A |
| 9/30/2017 | 11 | -10 | N/A | -3 | N/A |
| 6/30/2017 | 10 | -10 | N/A | -4 | N/A |
| 3/31/2017 | 9 | -12 | N/A | -5 | N/A |
| 12/31/2016 | 8 | -13 | N/A | -6 | N/A |
| 9/30/2016 | 7 | -12 | N/A | -6 | N/A |
| 6/30/2016 | 6 | -12 | N/A | -6 | N/A |
| 3/31/2016 | 6 | -15 | N/A | -6 | N/A |
| 12/31/2015 | 6 | -16 | N/A | -6 | N/A |
| 9/30/2015 | 5 | -15 | N/A | -5 | N/A |
| 6/30/2015 | 4 | -16 | N/A | -5 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: CYRX devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: CYRX devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: CYRX devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de CYRX ( 9.2% par an) devrait croître plus lentement que le marché de US ( 11.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de CYRX ( 9.2% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CYRX devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/11 06:07 |
| Cours de l'action en fin de journée | 2026/05/11 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Cryoport, Inc. est couverte par 14 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Yuan Zhi | B. Riley Securities, Inc. |